Development of a unique small molecule modulator of CXCR4
Zhongxing Liang1, Weiqiang Zhan, Aizhi Zhu
1Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States of America.
Background:
Metastasis, the spread and growth of tumor cells to distant organ sites, represents the most devastating attribute and plays a major role in the morbidity and mortality of cancer. Inflammation is crucial for malignant tumor transformation and survival. Thus, blocking inflammation is expected to serve as an effective cancer treatment. Among anti-inflammation therapies, chemokine modulation is now beginning to emerge from the pipeline. CXC chemokine receptor-4 (CXCR4) and its ligand stromal cell-derived factor-1 (CXCL12) interaction and the resulting cell signaling cascade have emerged as highly relevant targets since they play pleiotropic roles in metastatic progression. The unique function of CXCR4 is to promote the homing of tumor cells to their microenvironment at the distant organ sites.
Methodology/Principal Findings:
We describe the actions of N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine (designated MSX-122), a novel small molecule and partial CXCR4 antagonist with properties quite unlike that of any other reported CXCR4 antagonists, which was prepared in a single chemical step using a reductive amination reaction. Its specificity toward CXCR4 was tested in a binding affinity assay and a ligand competition assay using (18)F-labeled MSX-122. The potency of the compound was determined in two functional assays, Matrigel invasion assay and cAMP modulation. The therapeutic potential of MSX-122 was evaluated in three different murine models for inflammation including an experimental colitis, carrageenan induced paw edema, and bleomycin induced lung fibrosis and three different animal models for metastasis including breast cancer micrometastasis in lung, head and neck cancer metastasis in lung, and uveal melanoma micrometastasis in liver in which CXCR4 was reported to play crucial roles.
Conclusions/Significance:
We developed a novel small molecule, MSX-122, that is a partial CXCR4 antagonist without mobilizing stem cells, which can be safer for long-term blockade of metastasis than other reported CXCR4 antagonists.
Insights
A novel small molecule, MSX-122, acts as a partial CXCR4 antagonist. This new drug offers a potentially safer, long-term approach to blocking cancer metastasis by targeting inflammation and tumor cell homing.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Metastasis, the spread of cancer, is a major cause of cancer mortality.
- Inflammation is critical for cancer development and progression.
- Targeting chemokine pathways, like the CXC chemokine receptor-4 (CXCR4)/stromal cell-derived factor-1 (CXCL12) axis, is a promising anti-cancer strategy.
Purpose of the Study:
- To develop and characterize a novel small molecule antagonist for CXCR4.
- To evaluate the anti-inflammatory and anti-metastatic potential of the novel compound.
- To assess the safety profile of the antagonist for long-term use.
Main Methods:
- A novel partial CXCR4 antagonist, MSX-122, was synthesized via reductive amination.
- Compound specificity and potency were confirmed through binding, competition, invasion, and cAMP assays.
- Therapeutic efficacy was tested in murine models of inflammation and metastasis.
Main Results:
- MSX-122 demonstrated specificity and potency as a CXCR4 antagonist.
- The compound exhibited anti-inflammatory effects in colitis, paw edema, and lung fibrosis models.
- MSX-122 effectively reduced metastasis in breast, head and neck, and uveal melanoma models.
Conclusions:
- MSX-122 is a novel partial CXCR4 antagonist with significant anti-inflammatory and anti-metastatic properties.
- Unlike other antagonists, MSX-122 does not mobilize stem cells, suggesting improved safety for long-term metastasis blockade.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
08:22Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
Published on: May 31, 2020